Avelumab binds PD-L1 on target cells with its IgG1 Fc, engaging FcγR-expressing effector cells (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity (ADCC). It also blocks PD-1/PD-L1 to restore T-cell killing (indirect).